ASPIRINE PROTECT 100 mg

DRUG5 trials

Sponsors

Centre Hospitalier Universitaire De Caen Normandie, Centre Hospitalier Universitaire De Dijon, Assistance Publique Hopitaux De Paris, Centre Hospitalier Regional Et Universitaire De Brest, SORIN CRM SAS (Microport CRM)

Conditions

Acute Myocardial InfarctionAll adult patients with successful transfemoral trans-aortic valve implantation (TAVI ) for symptomatic aortic stenosis (AS) with no other indication for long term antiplatelet or anticoagulant therapyPatients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in naturePhiladelphia-negative myeloproliferative neoplasms are frequent and chronic myeloid malignancies including Polycythemia Vera (PV)Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF).acute pneumoniaand consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineuessential thrombocythemia (ET)

Phase 2

Short versus long antiplatelet therapy after TAVI

RecruitingCTIS2023-508208-40-00

Centre Hospitalier Universitaire De Caen NormandieAll adult patients with successful transfemoral trans-aortic valve implantation (TAVI ) for symptomatic aortic stenosis (AS) with no other indication for long term antiplatelet or anticoagulant therapy

Start: 2024-11-21Target: 1400Updated: 2025-05-07

Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myeloproliferative neoplasms

Not yet recruitingCTIS2024-515362-13-00

Centre Hospitalier Regional Et Universitaire De Brestessential thrombocythemia (ET), Philadelphia-negative myeloproliferative neoplasms are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis (PreMF).

Target: 1008Updated: 2025-07-11

Phase 3

ASPAPY - Aspirin in acute pneumonia in the elderly: a multicenter, double-blind, randomized, placebo-controlled trial

Not yet recruitingCTIS2024-510811-32-00

Centre Hospitalier Universitaire De Dijonacute pneumonia

Target: 600Updated: 2025-09-10

SERORL Effect of aspirin and folic acid for sudden sensorineural hearing loss

Not yet recruitingCTIS2024-513710-35-00

Assistance Publique Hopitaux De Parisand consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineu, occurs within a 72 hour window, Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature

Target: 142Updated: 2025-10-17

Phase 4

Evaluation of a modified Anti-Platelet Therapy associated with low-dose rapamycin DES Firehawk in Acute Myocardial Infarction Patients treated with complete revascularization strategy (TARGET-FIRST)

CompletedCTIS2024-519854-35-00

SORIN CRM SAS (Microport CRM)Acute Myocardial Infarction

Start: 2021-06-29End: 2025-03-24Target: 695Updated: 2025-04-14

Related Papers

ASPirin for Acute Pneumonia in the elderlY (ASPAPY): protocol of a multicentre randomised double-blind placebo-controlled trial

BMJ Open2025-05-01